Marc P. Bonaca, MD, FACC
Physician and Director of Vascular Research
CPC

Printed as of 11/28/2026

Disclosures

Personal Commercial (34)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abbott Laboratories	Research/Research Grants	Significant (>= $5,000)	
Agios Pharmaceuticals	Research/Research Grants	Significant (>= $5,000)	
Alexion Pharma	Research/Research Grants	Significant (>= $5,000)	
Alnylam	Research/Research Grants	Significant (>= $5,000)	
Amgen Inc.	Research/Research Grants	Significant (>= $5,000)	*Prevention*
Array	Research/Research Grants	Significant (>= $5,000)	
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ *PEGASUS-TIMI 54, REAL-TIMI 63B, ALETHEIA real world dataset*	Significant (>= $5,000)	*Prevention*
Atentiv	Research/Research Grants	Significant (>= $5,000)	
Bayer	Research/Research Grants ‡ *VOYAGER PAD*	Significant (>= $5,000)	*Prevention*
Bristol-Myers Squibb Company	Research/Research Grants	Significant (>= $5,000)	
CellResearch	Research/Research Grants	Significant (>= $5,000)	
Cleerly	Research/Research Grants	Significant (>= $5,000)	*Noninvasive Imaging*
Cleerly	Other - *Grant support to CPC*	Significant (>= $5,000)	*Prevention*
CSL Behring	Research/Research Grants	Significant (>= $5,000)	
Eidos Therapeutics	Research/Research Grants	Significant (>= $5,000)	
Epizon Pharma	Other - *Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director*	Significant (>= $5,000)	
Esperion	Research/Research Grants	Significant (>= $5,000)	
Fortress Biotech	Research/Research Grants	Significant (>= $5,000)	
Heartflow	Research/Research Grants	Significant (>= $5,000)	
Insmed	Research/Research Grants	Significant (>= $5,000)	
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ *PREVENT HD, VOYAGER PAD*	Significant (>= $5,000)	*Prevention*
Lexicon	Research/Research Grants	Significant (>= $5,000)	
Merck & Co., Inc.	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Novartis Corporation	Other - *Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director*	Significant (>= $5,000)	
NovoNordisk	Research/Research Grants	Significant (>= $5,000)	*Vascular Medicine*
Pfizer Inc	Research/Research Grants	Significant (>= $5,000)	
PhaseBio	Research/Research Grants	Significant (>= $5,000)	
Prothena Biosciences	Research/Research Grants	Significant (>= $5,000)	
Regeneron	Research/Research Grants	Significant (>= $5,000)	
Sanofi-Aventis	Research/Research Grants	Significant (>= $5,000)	
Silence Therapeutics	Other - *Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director*	Significant (>= $5,000)	
Stealth BioTherapeutics	Research/Research Grants	Significant (>= $5,000)	

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Teladoc Health	Salary	Significant (>= $5,000)	*Other*
VarmX	Other - *Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director*	Significant (>= $5,000)	

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American Heart Association	Other - *Chair of PAD Collaborative*	None ($0)	*Vascular Medicine*
Society of Vascular Medicine	Other - *Board of Trustees*	None ($0)	*Vascular Medicine*
Vascular Quality Initiative	Other - *Physician Safety Organization*	None ($0)	*Vascular Medicine*

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2013	aortic dissection	Defendant	Missed aortic dissection	Significant (>= $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/9/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/9/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/9/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/9/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.